Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (341-350 of 785) with videos related to

Pageof 79
Sort By:
Nephron|June 30, 2025
Expanded View of the Pathophysiology of Fabry DiseaseStanislav Kmoch, Martina Živná, Moran Dvela-Levitt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 21, 2011
Bone alkaline phosphatase and mortality in dialysis patientsChristiane Drechsler, Marion Verduijn, Stefan Pilz, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trialChristoph Wanner, Silvio E Inzucchi, Bernard Zinman, et al.
Journal of the American Society of Nephrology : JASN|July 12, 2014
HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patientsGünther Silbernagel, Bernd Genser, Christiane Drechsler, et al.
Clinical Therapeutics|September 27, 2016
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes MellitusTim Heise, Jens Jordan, Christoph Wanner, et al.
European Heart Journal|February 25, 2005
The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the diseaseFrank Weidemann, Frank Breunig, Meinrad Beer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 13, 2017
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on HemodialysisChristiane Drechsler, Salim S Hayek, Changli Wei, et al.
BMC Medical Genetics|February 16, 2013
Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2Lena Dörhöfer, Alexander Lammert, Vera Krane, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 25, 2014
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD studyChristiane Drechsler, Pieter Evenepoel, Marc G Vervloet, et al.
Plos One|November 22, 2017
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Mario Cebulla, et al.
Pageof 79

Showing results (341-350 of 785) with videos related to

Sort By:
Pageof 79
Nephron|June 30, 2025
Expanded View of the Pathophysiology of Fabry DiseaseStanislav Kmoch, Martina Živná, Moran Dvela-Levitt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 21, 2011
Bone alkaline phosphatase and mortality in dialysis patientsChristiane Drechsler, Marion Verduijn, Stefan Pilz, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trialChristoph Wanner, Silvio E Inzucchi, Bernard Zinman, et al.
Journal of the American Society of Nephrology : JASN|July 12, 2014
HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patientsGünther Silbernagel, Bernd Genser, Christiane Drechsler, et al.
Clinical Therapeutics|September 27, 2016
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes MellitusTim Heise, Jens Jordan, Christoph Wanner, et al.
European Heart Journal|February 25, 2005
The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the diseaseFrank Weidemann, Frank Breunig, Meinrad Beer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 13, 2017
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on HemodialysisChristiane Drechsler, Salim S Hayek, Changli Wei, et al.
BMC Medical Genetics|February 16, 2013
Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2Lena Dörhöfer, Alexander Lammert, Vera Krane, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 25, 2014
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD studyChristiane Drechsler, Pieter Evenepoel, Marc G Vervloet, et al.
Plos One|November 22, 2017
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Mario Cebulla, et al.
Pageof 79